NKGen Biotech (NKGN) Competitors $0.33 -0.01 (-2.22%) As of 06/13/2025 03:32 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKGN vs. OTLK, KLTO, XCUR, ADVM, ANL, CLSD, KLRS, ACHL, TELO, and PMVPShould you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Outlook Therapeutics (OTLK), Klotho Neurosciences (KLTO), Exicure (XCUR), Adverum Biotechnologies (ADVM), Adlai Nortye (ANL), Clearside Biomedical (CLSD), Allovir (KLRS), Achilles Therapeutics (ACHL), Telomir Pharmaceuticals (TELO), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical products" industry. NKGen Biotech vs. Its Competitors Outlook Therapeutics Klotho Neurosciences Exicure Adverum Biotechnologies Adlai Nortye Clearside Biomedical Allovir Achilles Therapeutics Telomir Pharmaceuticals PMV Pharmaceuticals NKGen Biotech (NYSE:NKGN) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability. Which has preferable earnings and valuation, NKGN or OTLK? Outlook Therapeutics has lower revenue, but higher earnings than NKGen Biotech. Outlook Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNKGen Biotech$80K185.41-$82.94M-$2.45-0.13Outlook TherapeuticsN/AN/A-$75.37M-$0.91-2.00 Does the media refer more to NKGN or OTLK? In the previous week, Outlook Therapeutics had 5 more articles in the media than NKGen Biotech. MarketBeat recorded 5 mentions for Outlook Therapeutics and 0 mentions for NKGen Biotech. Outlook Therapeutics' average media sentiment score of 0.49 beat NKGen Biotech's score of 0.00 indicating that Outlook Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment NKGen Biotech Neutral Outlook Therapeutics Neutral Which has more volatility & risk, NKGN or OTLK? NKGen Biotech has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Does the MarketBeat Community believe in NKGN or OTLK? Outlook Therapeutics received 167 more outperform votes than NKGen Biotech when rated by MarketBeat users. CompanyUnderperformOutperformNKGen BiotechN/AN/AOutlook TherapeuticsOutperform Votes16770.76% Underperform Votes6929.24% Do analysts recommend NKGN or OTLK? Outlook Therapeutics has a consensus target price of $9.60, suggesting a potential upside of 427.47%. Given Outlook Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Outlook Therapeutics is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do institutionals and insiders believe in NKGN or OTLK? 76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 11.2% of Outlook Therapeutics shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 4.8% of Outlook Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is NKGN or OTLK more profitable? Company Net Margins Return on Equity Return on Assets NKGen BiotechN/A N/A -479.36% Outlook Therapeutics N/A N/A -225.12% SummaryOutlook Therapeutics beats NKGen Biotech on 9 of the 14 factors compared between the two stocks. Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKGN vs. The Competition Export to ExcelMetricNKGen BiotechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$14.83M$3.09B$5.57B$19.68BDividend YieldN/A1.56%5.27%3.81%P/E Ratio-0.0632.6326.7834.98Price / Sales185.41455.18404.4942.86Price / CashN/A168.6838.2517.51Price / Book-0.123.366.964.78Net Income-$82.94M-$72.35M$3.23B$1.02B7 Day Performance-2.94%0.36%-1.24%0.82%1 Month Performance-8.33%16.48%8.34%1.74%1 Year Performance-75.56%-15.35%33.30%10.57% NKGen Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKGNNKGen Biotech0.807 of 5 stars$0.33-2.2%N/A-75.0%$14.83M$80K-0.06N/AOTLKOutlook Therapeutics1.4054 of 5 stars$1.84-3.4%$9.60+423.2%-76.2%$61.93MN/A-0.2520Gap DownKLTOKlotho NeurosciencesN/A$1.90+4.5%N/AN/A$61.77MN/A-5.28N/AGap DownHigh Trading VolumeXCURExicure1.7966 of 5 stars$9.75+0.5%N/A+2,513.4%$61.60M$500K-4.7150ADVMAdverum Biotechnologies3.9429 of 5 stars$2.94-1.0%$26.40+798.0%-69.6%$61.42M$1M-0.49190Short Interest ↑Gap DownANLAdlai Nortye1.4758 of 5 stars$1.66+3.1%$9.00+442.2%-50.2%$61.25M$5M0.00127CLSDClearside Biomedical2.6099 of 5 stars$0.79+4.2%$4.80+505.3%-35.0%$61.00M$3.76M-1.7430Positive NewsShort Interest ↓Gap DownKLRSAllovirN/A$3.26+6.5%N/AN/A$60.97MN/A0.00110ACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250News CoverageTELOTelomir Pharmaceuticals2.2473 of 5 stars$2.02+2.0%$15.00+642.6%-65.2%$59.97MN/A-3.471News CoveragePMVPPMV Pharmaceuticals2.4085 of 5 stars$1.15+8.0%$5.50+380.3%-37.9%$59.49MN/A-1.1550Positive NewsGap Down Related Companies and Tools Related Companies Outlook Therapeutics Alternatives Klotho Neurosciences Alternatives Exicure Alternatives Adverum Biotechnologies Alternatives Adlai Nortye Alternatives Clearside Biomedical Alternatives Allovir Alternatives Achilles Therapeutics Alternatives Telomir Pharmaceuticals Alternatives PMV Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NKGN) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
